Endogenous thiol tripeptide / cellular redox buffer
Glutathione is a small molecule your body makes to help control redox balance and process peroxides and reactive chemicals. People research it for antioxidant support, skin pigmentation, liver health, recovery, breathing conditions, and general wellness. Oral glutathione can raise measured glutathione, but stronger clinical benefits are inconsistent, route-specific, or not demonstrated. Injectable products add sterility and endotoxin risks.
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Research at a glance
Depth and confidence summarize the research record—not effectiveness, safety, or a recommendation.
Controlled oral, inhaled, intravenous, and topical studies examine biomarkers and disease-specific outcomes using very different formulations.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
Oral target engagement is reproducible, but meaningful clinical effects are inconsistent, route-specific, and often unsupported by larger trials.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not a suggested amount.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: Higher measured glutathione does not automatically mean better symptoms, performance, recovery, liver health, or longevity. Branded formulations and milligram amounts are not interchangeable. Amounts shown describe cited research exposure—not a dosage recommendation.
Practical starting point
Common goals and questions—not recommendations or promises of benefit.
The overview, studies, and source ledger below explain what supports each label—and where the evidence stops.
The short version
Glutathione is a small molecule your body makes to help control redox balance and process peroxides and reactive chemicals. People research it for antioxidant support, skin pigmentation, liver health, recovery, breathing conditions, and general wellness. Oral glutathione can raise measured glutathione, but stronger clinical benefits are inconsistent, route-specific, or not demonstrated. Injectable products add sterility and endotoxin risks.
Evidence reviewed through July 25, 2026. Direct glutathione is separated from NAC, GlyNAC, cysteine, glycine, glutamine, and combination products. Oral, topical, inhaled, and intravenous evidence are not treated as interchangeable.
What the evidence says
Controlled oral trials show that direct glutathione can raise glutathione biomarkers; larger condition-specific trials show that target delivery does not necessarily improve clinical outcomes
This is the strongest supported conclusion in the current human evidence—not a summary of every claim made about the compound.
Which formulation- and route-specific biomarker changes, if any, translate into meaningful durable health outcomes and what long-term safety looks like
Keeping the main uncertainty visible prevents an early or promising finding from looking more settled than it is.
The evidence story
Importance shows how much an item changes the evidence story. Quality shows how much confidence the design deserves. A strong negative study can score highly on both.
Importance and quality answer different questions. A rigorous study can be highly important even when it challenges a popular claim.
The branded micellar formulation produced higher baseline-adjusted glutathione exposure and peak response than the standard preparation at the administered doses. Thirty-day clinical safety markers did not change significantly.
Small oral and topical studies reported some melanin-index improvement, but effects were variable, not durable, and supported by a mixed-quality evidence base. The single IV study was not convincingly positive.
Oral glutathione did not significantly improve growth, BMI, inflammatory markers, or the other secondary outcomes compared with placebo. It was generally well tolerated.
FDA investigated acute reactions linked to compounded IV glutathione and found excessive bacterial endotoxin in the implicated bulk ingredient, demonstrating a product-quality risk separate from intrinsic glutathione pharmacology.
Both oral glutathione groups increased measured glutathione in several body compartments. Larger and longer exposure generally produced larger changes, and levels returned toward baseline after washout.
Administration and handling
Human studies used oral, inhaled, topical, and intravenous glutathione for different questions. Oral studies ranged from single pharmacokinetic exposures to months-long supplementation; inhaled and IV studies used disease-specific clinical protocols. These are study descriptions, not recommendations. Evidence from one route, formulation, or oxidation state cannot define another route's dose, frequency, compatibility, effectiveness, or safety.
Reduced glutathione can oxidize to GSSG, and formulation-specific stability, packaging, temperature, light exposure, concentration, and beyond-use limits cannot be generalized. No FDA-approved injectable glutathione label was located from which to derive consumer reconstitution, diluent, compatibility, or storage instructions. FDA has documented acute reactions linked to excessive bacterial endotoxin in a bulk ingredient used for compounded sterile injections.
Primary-source ledger
2026-03-01 · PMID 41897500 · NCT06345950 · DOI 10.3390/antiox15030354
2025-06-01 · PMID 39444151 · DOI 10.1111/ijd.17535
2020-12-01 · PMID 32960827 · NCT03020719 · DOI 10.1097/MPG.0000000000002948
2019-06-07
2015-03-01 · PMID 24791752 · NCT01044277 · DOI 10.1007/s00394-014-0706-z
2013-07-01 · PMID 23631796 · NCT00506688 · DOI 10.1164/rccm.201303-0427OC
2009-05-15 · PMID 19230029 · DOI 10.1002/mds.22401